SUPPLEMENTARY DATA

STAT3/NF-κB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer

Rômulo S. Cavalcante[a,b], Uta Ishikawa[b], Emanuell S. Silva[d,e], Arnóbio A. Silva Júnior[a,d,e], Aurigena A. Araújo[c], Luis J. Cruz[f], Alan B. Chan[f,g], Raimundo F. Araújo Júnior[1,2,7*]

[a]Postgraduate Program in Health Science, Federal University of Rio Grande do Norte, 59064 741, Natal, RN, Brazil.

[b]Cancer and Inflammation Research Laboratory, Department of Morphology, Federal University of Rio Grande do Norte, 59064 741, Natal, RN, Brazil.

[c]Postgraduate Program in Pharmaceutical Science, Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, 59064 741, Natal, RN, Brazil.

[d]Postgraduate Program in Development and Technological Innovation in Medicines, Federal University of Rio Grande do Norte, Natal, RN, Brazil.

[e]Laboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte, 59012 570, Natal, RN, Brazil.

[f]Translational Nanobiomaterials and Imaging, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

[g]Percuros B.V, Zernikedreef 8, 2333 CL, Leiden, The Netherlands.

Data available on request from the authors

Corresponding author: Raimundo Fernandes de Araújo Júnior, Radiology Department/ Leiden University Medical Centre, Leiden, The Netherlands. Post code: 2333 ZA. +31655620247. **araujojr@cb.ufrn.br**

SUPPLEMENTARY FIGURE LEGENDS



Supplementary Fig. S1: Cell viability after treatment with PLGA nanoparticles. Different formulations of PeiPLGA NPs, as well as their isolated constituents, were performed in 4T1 breast

cancer cells (A-F) and HEK-293 kidney embryonic cells (G-L). IC_{50} of each test was assessed. One-way ANOVA with post-hoc Bonferroni correction; *, P<0.05. All data are presented as mean ± SD of five independent assays with at least three replicates.



Supplementary Fig. S2: *In vivo* toxicity of NPs. The different formulations of PeiPLGA NPs were tested in female BALB/c mice after intraperitoneal administration of NPs every five days for fifteen days. Hepatic (A, C, E, G, I, K) and pulmonary (B, D, F, H, J, L) tissues were evaluated histologically. The arrowheads indicate inflammatory sites. In the lower right corner of each image a 400x magnification of is shown. Systemic toxicity by measuring biochemical markers of liver and kidney injury (M-P). One-way ANOVA with post-hoc Bonferroni correction or Kruskal-Wallis with post-hoc Dunn correction; *, P<0.05; #, no significant difference. All data are presented as mean ± SD of six independent values (*n* = 6) per group.